Heparanase is required for activation and function of macrophages

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 48, 2016, Pages E7808-E7817

  Gutter Kapon, Lilach ^a   Alishekevitz, Dror ^a   Shaked, Yuval ^a   Li, Jin Ping ^b   Aronheim, Ami ^a   Ilan, Neta ^a   Vlodavsky, Israel ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Cytokine expression; Heparanase; Knockout mice; Macrophage; Tumor growth

Indexed keywords

CHEMOKINE RECEPTOR CXCR2; HEPARANASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LYSOZYME; MACROPHAGE INFLAMMATORY PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN C FOS; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR; VASCULOTROPIN A; VASCULOTROPIN C; BETA GLUCURONIDASE; CYTOKINE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL ISOLATION; CELL MOTILITY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; ENZYME ACTIVITY; KNOCKOUT MOUSE; LEWIS CARCINOMA; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; MONOCYTE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; WILD TYPE MOUSE; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CELL LINE; ENZYMOLOGY; GENE EXPRESSION REGULATION; IMMUNOLOGY; MACROPHAGE; METABOLISM; PATHOLOGY; PHYSIOLOGY; TRANSCRIPTION INITIATION; TUMOR VOLUME;

ANIMALS; CARCINOMA, LEWIS LUNG; CELL LINE; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONIDASE; MACROPHAGE ACTIVATION; MACROPHAGES; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TUMOR BURDEN; TUMOR MICROENVIRONMENT;

EID: 84999208602     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1611380113     Document Type: Article

References (52)

1. Nakajima M, Irimura T, Di Ferrante D, Di Ferrante N, Nicolson GL (1983) Heparan sulfate degradation: Relation to tumor-invasive and metastatic properties of mouse B16 melanoma sublines. Science 220(4597):611-613.
2. Vlodavsky I, Fuks Z, Bar-Ner M, Ariav Y, Schirrmacher V (1983) Lymphoma cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: Relationship to tumor cell metastasis. Cancer Res 43(6):2704-2711.
3. Hammond E, Khurana A, Shridhar V, Dredge K (2014) The role of heparanase and sulfatases in the modification of heparan sulfate proteoglycans within the tumor microenvironment and opportunities for novel cancer therapeutics. Front Oncol 4:195.
4. Ilan N, Elkin M, Vlodavsky I (2006) Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 38(12):2018-2039.
5. Vreys V, David G (2007) Mammalian heparanase: What is the message? J Cell Mol Med 11(3):427-452.
6. Vlodavsky I, et al. (2012) Significance of heparanase in cancer and inflammation. Cancer Microenviron 5(2):115-132.
7. Casu B, Vlodavsky I, Sanderson RD (2008) Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb 36(3-4):195-203.
8. Vlodavsky I, Ilan N, Naggi A, Casu B (2007) Heparanase: Structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des 13(20):2057-2073.
9. Arvatz G, Shafat I, Levy-Adam F, Ilan N, Vlodavsky I (2011) The heparanase system and tumor metastasis: Is heparanase the seed and soil? Cancer Metastasis Rev 30(2):253-268.
10. Barash U, et al. (2014) Heparanase enhances myeloma progression via CXCL10 downregulation. Leukemia 28(11):2178-2187.
11. Boyango I, et al. (2014) Heparanase cooperates with Ras to drive breast and skin tumorigenesis. Cancer Res 74(16):4504-4514.
12. Ramani VC, et al. (2016) Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma. Oncotarget 7(2):1598-1607.
13. Shteingauz A, et al. (2015) Heparanase enhances tumor growth and chemoresistance by promoting autophagy. Cancer Res 75(18):3946-3957.
14. Weissmann M, et al. (2016) Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis. Proc Natl Acad Sci USA 113(3):704-709.
15. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3(5):391-400.
16. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883-899.
17. Mantovani A, Sica A (2010) Macrophages, innate immunity and cancer: Balance, tolerance, and diversity. Curr Opin Immunol 22(2):231-237.
18. Biswas SK, Sica A, Lewis CE (2008) Plasticity of macrophage function during tumor progression: Regulation by distinct molecular mechanisms. J Immunol 180(4):2011-2017.
19. De Palma M, Lewis CE (2013) Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 23(3):277-286.
20. Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat Immunol 11(10):889-896.
21. Lakshmi Narendra B, Eshvendar Reddy K, Shantikumar S, Ramakrishna S (2013) Immune system: A double-edged sword in cancer. Inflamm Res 62(9):823-834.
22. Lamagna C, Aurrand-Lions M, Imhof BA (2006) Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol 80(4):705-713.
23. Mills CD, Lenz LL, Harris RA (2016) A breakthrough: Macrophage-directed cancer immunotherapy. Cancer Res 76(3):513-516.
24. Zcharia E, et al. (2009) Newly generated heparanase knock-out mice unravel coregulation of heparanase and matrix metalloproteinases. PLoS One 4(4):e5181.
25. Blich M, et al. (2013) Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. Arterioscler Thromb Vasc Biol 33(2):e56-e65.
26. Driscoll KE (1994) Macrophage inflammatory proteins: Biology and role in pulmonary inflammation. Exp Lung Res 20(6):473-490.
27. Doloff JC, Chen CS, Waxman DJ (2014) Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2. Mol Cancer 13:158.
28. Gorczyca W, et al. (2011) Immunophenotypic pattern of myeloid populations by flow cytometry analysis. Methods Cell Biol 103:221-266.
29. Lider O, et al. (1990) Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity. Eur J Immunol 20(3):493-499.
30. Hermano E, et al. (2014) Macrophage polarization in pancreatic carcinoma: Role of heparanase enzyme. J Natl Cancer Inst 106(12):dju332.
31. Barash U, et al. (2010) Proteoglycans in health and disease: New concepts for heparanase function in tumor progression and metastasis. FEBS J 277(19):3890-3903.
32. Morris A, et al. (2015) The role of heparanase in pulmonary cell recruitment in response to an allergic but not non-allergic stimulus. PLoS One 10(6): e0127032.
33. Petrovich E, et al. (2016) Lung ICAM-1 and ICAM-2 support spontaneous intravascular effector lymphocyte entrapment but are not required for neutrophil entrapment or emigration inside endotoxin-inflamed lungs. FASEB J 30(5):1767-1778.
34. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23(11):549-555.
35. Bingle L, Brown NJ, Lewis CE (2002) The role of tumour-associated macrophages in tumour progression: Implications for new anticancer therapies. J Pathol 196(3):254-265.
36. Talmadge JE, Donkor M, Scholar E (2007) Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev 26(3-4):373-400.
37. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12(4):253-268.
38. Chen CS, Doloff JC, Waxman DJ (2014) Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression. Neoplasia 16(1):84-96.
39. Forssell J, et al. (2007) High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 13(5):1472-1479.
40. Rivera LB, Bergers G (2013) Location, location, location: Macrophage positioning within tumors determines pro- or antitumor activity. Cancer Cell 24(6):687-689.
41. Sun Y, Lodish HF (2010) Adiponectin deficiency promotes tumor growth in mice by reducing macrophage infiltration. PLoS One 5(8):e11987.
42. He YQ, et al. (2012) The endoglycosidase heparanase enters the nucleus of T lymphocytes and modulates H3 methylation at actively transcribed genes via the interplay with key chromatin modifying enzymes. Transcription 3(3):130-145.
43. Goodall KJ, Poon IK, Phipps S, Hulett MD (2014) Soluble heparan sulfate fragments generated by heparanase trigger the release of pro-inflammatory cytokines through TLR-4. PLoS One 9(10):e109596.
44. Bode JG, Ehlting C, Häussinger D (2012) The macrophage response towards LPS and its control through the p38(MAPK)-STAT3 axis. Cell Signal 24(6):1185-1194.
45. Guha M, Mackman N (2001) LPS induction of gene expression in human monocytes. Cell Signal 13(2):85-94.
46. Gingis-Velitski S, et al. (2011) Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice. Cancer Res 71(22):6986-6996.
47. Gingis-Velitski S, Zetser A, Flugelman MY, Vlodavsky I, Ilan N (2004) Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem 279(22):23536-23541.
48. Vlodavsky I (1999) Preparation of extracellular matrices produced by cultured corneal endothelial and PF-HR9 endodermal cells. Curr Protoc Cell Biol Chapter 10:Unit 10.4.
49. Li Y, et al. (2013) Suppression of endoplasmic reticulum stress-induced invasion and migration of breast cancer cells through the downregulation of heparanase. Int J Mol Med 31(5):1234-1242.
50. Hwang ES, Hong JH, Bae SC, Ito Y, Lee SK (1999) Regulation of c-fos gene transcription and myeloid cell differentiation by acute myeloid leukemia 1 and acute myeloid leukemia-MTG8, a chimeric leukemogenic derivative of acute myeloid leukemia 1. FEBS Lett 446(1):86-90.
51. Kehat I, et al. (2006) Inhibition of basic leucine zipper transcription is a major mediator of atrial dilatation. Cardiovasc Res 70(3):543-554.
52. Voloshin T, et al. (2015) Blocking IL1β pathway following paclitaxel chemotherapy slightly inhibits primary tumor growth but promotes spontaneous metastasis. Mol Cancer Ther 14(6):1385-1394.